ALEC

Business Context and Reporting Period

Alector, Inc. (ALEC) is a late-stage clinical biotechnology company focused on developing therapies for neurodegenerative diseases, including frontotemporal dementia (FTD), Alzheimer's disease (AD), and Parkinson's disease (PD). The company operates in a single segment and relies heavily on collaboration agreements, primarily with GlaxoSmithKline (GSK), for funding and development. This report covers the quarterly period ended March 31, 2025.

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held $37.9 million in cash and cash equivalents and $316.6 million in marketable securities. Management anticipates this capital provides a runway into the second half of 2027.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased by $12.2 million (77%) compared to Q1 2024. This was primarily due to the satisfaction of performance obligations associated with the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in the fourth quarter of 2024.
• Expense Reduction: Total operating expenses decreased by $11.2 million. Research and Development (R&D) expenses dropped $11.5 million, driven by reduced costs for the AL002 program and personnel cost reductions following workforce reductions.
• Restructuring: The company initiated a reduction in force impacting approximately 25 employees (13% of the workforce) in March 2025, incurring $2.3 million in restructuring costs included in operating expenses for the quarter.
• Collaboration Termination: The AbbVie collaboration agreement was terminated in February 2025 following the failure of the AL002 Phase 2 trial to meet its primary endpoint in late 2024.

Outlook, Risks, and Management Commentary

• Clinical Pipeline Status:
  • Latozinemab (AL001): In a pivotal Phase 3 trial (INFRONT-3) for FTD-GRN. Topline data is anticipated in Q4 2025.
  • AL101: In a Phase 2 trial (PROGRESS-AD) for early Alzheimer's disease. Enrollment was completed in April 2025.
  • Preclinical: Advancing ADP037-ABC (anti-amyloid beta) and ADP050-ABC (GCase replacement therapy) utilizing the proprietary Alector Brain Carrier (ABC) technology.
• Capital Requirements: The company expects to continue incurring net losses for the foreseeable future. While current cash reserves are projected to fund operations into late 2027, the company may seek additional financing through equity, debt, or collaborations.
• Risks:
  • Development Risk: High uncertainty in drug development; failure of clinical trials (e.g., AL002) can lead to program termination and loss of milestone revenue.
  • Collaboration Dependency: Significant reliance on GSK for development and commercialization of key assets. GSK retains the right to terminate the agreement.
  • Regulatory and Market Risk: Potential delays in FDA/EMA approvals, competition from approved Alzheimer's therapies (e.g., lecanemab, donanemab), and potential impacts of healthcare legislation on pricing and reimbursement.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2027" runway estimate given the recent restructuring and ongoing burn rate.
• GSK Agreement Terms: Review the specific cost-sharing obligations and refund liabilities ($44.6 million as of March 31, 2025) associated with the GSK collaboration.
• AL002 Termination Impact: Confirm the full financial impact of the AbbVie termination, including the loss of potential milestone payments and the reversion of rights.
• INFRONT-3 Trial Timeline: Monitor the Q4 2025 data readout for latozinemab, which is critical for the company's near-term valuation.
• Debt Covenants: Review the terms of the $50 million loan facility with Hercules Capital, specifically the covenants and the status of the second tranche availability.